Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
About this episode
Dr. Raphael Schneider discusses the impact of multiplex proteomic biomarker panels on understanding and monitoring multiple sclerosis.
Guest: Raphael Schneider, MD, PhD, FRCPC, CIP Multiplex proteomic biomarker panels are redefining how we understand and monitor multiple sclerosis (MS) by capturing interconnected pathways in a single sample. Hear from Dr. Raphael Schneider as he explores how these tools could inform prognosis, risk stratification, and clinical trial design, which he spoke about at the 2026 ACTRIMS Forum. Dr. Schneider is a neurologist and researcher at the BARLO MS Centre at St. Michael’s Hospital as well as an Assistant Professor and the Elizabeth S. Barford Early Career Professor in Multiple Sclerosis in the Department of Medicine at the University of Toronto.
More episodes of NeuroFrontiers
- Cognitive Screening in MS: Practical Strategies and Modern Approaches
- Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
- Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
- Examining the Global Genetic Prevalence of TK2d
- Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
- Understanding Accelerated Biological Aging in Pediatric MS
Explore listener stats, chart rankings, contacts and more on the NeuroFrontiers podcast page.